Abstract
Thirty patients with high-risk myelodysplastic syndrome, defined as>5% bone marrow blasts, were treated with a combination of oral all-trans-retinoic acid (45 mg/m2 daily) and subcutaneous AraC (10 mg/m2) on days 1-14 of each 28-35 day cycle repeated for 2-6 cycles. Complete remission lasting 9, 12, and 15 months was achieved in three patients. Partial and minor response did not translate into meaningful clinical improvement, like complete responders. Overall incidence of leukemia transformation and survival of this cohort of patients was no different from the expected outcome for a group of patients with similar characteristics. Copyright (C) 1999 Elsevier Science Ltd.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 811-815 |
| Number of pages | 5 |
| Journal | Leukemia Research |
| Volume | 23 |
| Issue number | 9 |
| DOIs | |
| State | Published - Sep 1999 |
Fingerprint
Keywords
- Chemotherapy
- Leukemia
- Myelodysplastic syndrome
- Treatment
ASJC Scopus subject areas
- Cancer Research
- Hematology
- Oncology
Cite this
Treatment of unfavorable myelodysplastic syndrome with all-trans-retinoic acid and subcutaneous Ara C. / Letendre, Louis; Noel, Pierre; White, William L.; Tefferi, Ayalew; Litzow, Mark R; Li, Chin Yang; Schroeder, Georgene.
In: Leukemia Research, Vol. 23, No. 9, 09.1999, p. 811-815.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Treatment of unfavorable myelodysplastic syndrome with all-trans-retinoic acid and subcutaneous Ara C
AU - Letendre, Louis
AU - Noel, Pierre
AU - White, William L.
AU - Tefferi, Ayalew
AU - Litzow, Mark R
AU - Li, Chin Yang
AU - Schroeder, Georgene
PY - 1999/9
Y1 - 1999/9
N2 - Thirty patients with high-risk myelodysplastic syndrome, defined as>5% bone marrow blasts, were treated with a combination of oral all-trans-retinoic acid (45 mg/m2 daily) and subcutaneous AraC (10 mg/m2) on days 1-14 of each 28-35 day cycle repeated for 2-6 cycles. Complete remission lasting 9, 12, and 15 months was achieved in three patients. Partial and minor response did not translate into meaningful clinical improvement, like complete responders. Overall incidence of leukemia transformation and survival of this cohort of patients was no different from the expected outcome for a group of patients with similar characteristics. Copyright (C) 1999 Elsevier Science Ltd.
AB - Thirty patients with high-risk myelodysplastic syndrome, defined as>5% bone marrow blasts, were treated with a combination of oral all-trans-retinoic acid (45 mg/m2 daily) and subcutaneous AraC (10 mg/m2) on days 1-14 of each 28-35 day cycle repeated for 2-6 cycles. Complete remission lasting 9, 12, and 15 months was achieved in three patients. Partial and minor response did not translate into meaningful clinical improvement, like complete responders. Overall incidence of leukemia transformation and survival of this cohort of patients was no different from the expected outcome for a group of patients with similar characteristics. Copyright (C) 1999 Elsevier Science Ltd.
KW - Chemotherapy
KW - Leukemia
KW - Myelodysplastic syndrome
KW - Treatment
UR - http://www.scopus.com/inward/record.url?scp=0032780477&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0032780477&partnerID=8YFLogxK
U2 - 10.1016/S0145-2126(99)00095-8
DO - 10.1016/S0145-2126(99)00095-8
M3 - Article
VL - 23
SP - 811
EP - 815
JO - Leukemia Research
JF - Leukemia Research
SN - 0145-2126
IS - 9
ER -